These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 10450749)

  • 21. Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques.
    Harousseau JL; Witz B; Lioure B; Hunault-Berger M; Desablens B; Delain M; Guilhot F; Le Prise PY; Abgrall JF; Deconinck E; Guyotat D; Vilque JP; Casassus P; Tournilhac O; Audhuy B; Solary E
    J Clin Oncol; 2000 Feb; 18(4):780-7. PubMed ID: 10673519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome.
    Rossi HA; O'Donnell J; Sarcinelli F; Stewart FM; Quesenberry PJ; Becker PS
    Leukemia; 2002 Mar; 16(3):310-5. PubMed ID: 11896533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia.
    Visani G; Milligan D; Leoni F; Chang J; Kelsey S; Marcus R; Powles R; Schey S; Covelli A; Isidori A; Litchman M; Piccaluga PP; Mayer H; Malagola M; Pfister C
    Leukemia; 2001 May; 15(5):764-71. PubMed ID: 11368437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse.
    Büchner T; Hiddemann W; Koenigsmann M; Zühlsdorf M; Wörmann B; Boeckmann A; Freire EA; Innig G; Maschmeyer G; Ludwig WD
    Blood; 1991 Sep; 78(5):1190-7. PubMed ID: 1878586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.
    Thomas X; Suciu S; Rio B; Leone G; Broccia G; Fillet G; Jehn U; Feremans W; Meloni G; Vignetti M; de Witte T; Amadori S
    Haematologica; 2007 Mar; 92(3):389-96. PubMed ID: 17339189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997.
    Cripe LD; Rader K; Tallman MS; Gordon MS; Paietta E; Bennett J; Neuberg D; Litzow MR; O'brien TE; Rowe JM
    Leuk Res; 2006 Jul; 30(7):823-7. PubMed ID: 16413056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia.
    Thomas X; Cambier N; Taksin AL; Reman O; Vekhoff A; Pautas C; Leblond V; Soler-Michel P; Ecstein-Fraïssé E; Archimbaud E
    Leuk Res; 2000 Nov; 24(11):957-63. PubMed ID: 11086179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
    Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
    Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Timed sequential chemotherapy for advanced acute myeloid leukemia.
    Archimbaud E; Leblond V; Fenaux P; Dombret H; Cordonnier C; Dreyfus F; Cony-Makhoul P; Tilly H; Troussard X; Auzanneau G; Thomas X; Ffrench M; Marie JP
    Hematol Cell Ther; 1996 Apr; 38(2):161-7. PubMed ID: 8931997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro and in vivo effects of rh GM-CSF in acute myeloid leukemia (AML).
    Wörmann B; Hiddemann W; Frisch J; Zühlsdorf M; Rottmann R; Boeckmann A; Reuter C; Freire EA; Innig G; Schulz G
    Behring Inst Mitt; 1991 Dec; (90):28-38. PubMed ID: 1801688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine.
    Stone RM; Berg DT; George SL; Dodge RK; Paciucci PA; Schulman PP; Lee EJ; Moore JO; Powell BL; Baer MR; Bloomfield CD; Schiffer CA
    Blood; 2001 Aug; 98(3):548-53. PubMed ID: 11468148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.
    Zittoun R; Suciu S; Mandelli F; de Witte T; Thaler J; Stryckmans P; Hayat M; Peetermans M; Cadiou M; Solbu G; Petti MC; Willemze R
    J Clin Oncol; 1996 Jul; 14(7):2150-9. PubMed ID: 8683249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
    Hänel M; Friedrichsen K; Hänel A; Herbst R; Morgner A; Neser S; Nicklisch M; Teich M; Ehninger G; Fiedler F
    Onkologie; 2001 Aug; 24(4):356-60. PubMed ID: 11574763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
    Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
    J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia. German AML Cooperative Group.
    Kern W; Aul C; Maschmeyer G; Kuse R; Kerkhoff A; Grote-Metke A; Eimermacher H; Kubica U; Wörmann B; Büchner T; Hiddemann W
    Ann Hematol; 1998 Sep; 77(3):115-22. PubMed ID: 9797080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Current and new therapeutic strategies in acute myeloid leukemia].
    Naito K; Ohnishi K
    Gan To Kagaku Ryoho; 2005 Mar; 32(3):292-6. PubMed ID: 15791811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial.
    Thomas X; Elhamri M; Chelghoum Y; Reman O; Arnaud P; Raffoux E; Le QH; Tavernier E; Dombret H; Michallet M
    Ann Hematol; 2005 Jun; 84(6):376-82. PubMed ID: 15782343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
    Halpern AB; Othus M; Huebner EM; Buckley SA; Pogosova-Agadjanyan EL; Orlowski KF; Scott BL; Becker PS; Hendrie PC; Chen TL; Percival MM; Estey EH; Stirewalt DL; Walter RB
    Leukemia; 2017 Dec; 31(12):2560-2567. PubMed ID: 28555084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490).
    Rowe JM; Andersen JW; Mazza JJ; Bennett JM; Paietta E; Hayes FA; Oette D; Cassileth PA; Stadtmauer EA; Wiernik PH
    Blood; 1995 Jul; 86(2):457-62. PubMed ID: 7605984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.